This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot study


Beauchet, Olivier, Launay, Cyrille P., Allali, Gazan, Watfa, Gilles, Gallouj, Karim, Herrmann, François R., Annweiler, Cedric


BMC Neurology, Volume: 13, Pages.: 184-184

Year of Publication



Background: Anti-dementia drugs may improve gait performance. No comparison between acetylcholinesterase inhibitors (CEIs) and memantine-related changes in gait variability has been reported. The objectives of this study were to 1) quantify and compare the mean values and coefficients of variation (CoV) of stride time in demented patients with Alzheimer’s disease and related disorders (ADRD) before and after the use of CEIs or memantine, and in age- and gender-matched controls patients with ADRD using no anti-dementia drugs; and 2) to determine whether changes in CoV of stride time differed between CEIs or memantine.; Methods: A total of 120 demented patients with mild-to-moderate ADRD were prospectively included in this pre-post quasi-experimental study with two intervention groups (43 patients taking CEIs, and 41 taking memantine) and a control group (36 age- and gender matched patients without any anti-dementia drugs). CoV of stride time and walking speed were measured with GAITRite® system while usual walking at steady state. Age, gender, number of drugs daily taken, use of psychoactive drugs, body mass index and time between the two visits were also recorded.; Results: There was no difference between groups for the time between baseline and follow-up assessments (232.9 ± 103.7 days for patients without anti-dementia drugs, 220.0 ± 67.5 days for patients with CEIs, 186.7 ± 96.2 days for patients with memantine, P = 0.062). Patients with memantine had a lower (i.e., better) CoV of stride time at follow-up assessment compared to those with CEIs (4.2 ± 2.4% versus 5.8 ± 4.2%, P = 0.010). Patients with memantine had a greater decrease in CoV of stride time compared to those with CEIs (-1.90% versus 0.93%, P = 0.010) and mixed-effects linear regressions showed that this decrease was specifically explained by memantine (P = 0.028).; Conclusions: Our results showed that patients with ADRD and treated with memantine, but not those with CEIs, decreased their gait variability, and thus improved their gait safety (Trial registration number: NCT01315704).;

Bibtex Citation

@article{Beauchet_2013, doi = {10.1186/1471-2377-13-184}, url = {}, year = 2013, month = {nov}, publisher = {Springer Nature}, volume = {13}, number = {1}, author = {Olivier Beauchet and Cyrille P Launay and Gazan Allali and Gilles Watfa and Karim Gallouj and Fran{c{c}}ois R Herrmann and C{'{e}}dric Annweiler}, title = {Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot study}, journal = {{BMC} Neurology} }


aged, aged, 80 and over, alzheimer disease, cholinesterase inhibitors, dementia, diagnosis, drug effects, drug therapy, female, gait, humans, male, memantine, pharmacology, physiology, pilot projects, prospective studies, therapeutic use

Countries of Study


Types of Dementia

Dementia (general / unspecified)

Types of Study

Case Control Study

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime